Form 4: Pfizer CEO Albert Bourla Granted 708,666 Stock Appreciation Rights

Pfizer's Chairman and CEO, Albert Bourla, was granted 708,666 Stock Appreciation Rights with an exercise price of $26.58, vesting on March 3, 2031.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc. (PFE), was granted 708,666 Stock Appreciation Rights (SARs).
• The transaction date for this grant was March 3, 2026.
• The exercise price for these SARs is $26.58.
• The SARs are subject to certain vesting requirements and will be settled in shares of Pfizer common stock.
• Settlement will occur on the fifth anniversary of the grant date, which is March 3, 2031.
• Following this transaction, Albert Bourla beneficially owns 708,666 derivative securities (SARs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event. The grant of equity incentives is generally positive for aligning management interests with shareholders, but it does not provide new operational or financial performance insights.

Positives

• The grant of Stock Appreciation Rights aligns the interests of the CEO with those of shareholders, as the value of the SARs increases with Pfizer's stock price appreciation.
• Equity compensation is a standard practice for executive remuneration, incentivizing long-term performance and retention.

Future Outlook

The Stock Appreciation Rights are subject to vesting requirements and are scheduled to be settled in shares of Pfizer common stock on March 3, 2031, indicating a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that the grant of Stock Appreciation Rights is a common form of long-term incentive compensation for executives in the pharmaceutical industry and across large public companies. This practice aims to align executive performance with shareholder value creation over several years.

Comparison to Industry Standards

• The grant of equity-based compensation like SARs is a standard component of executive pay packages across major pharmaceutical companies, similar to practices at competitors like Johnson & Johnson or Merck & Co. The specific size of the grant would typically be benchmarked against peer group compensation data, considering company size, performance, and the executive's role and tenure. Without specific peer compensation data, a direct quantitative comparison is not feasible from this filing alone.

Related Party Transactions

• This filing reports an equity grant to the Chairman and CEO, Albert Bourla, which is a form of executive compensation and an insider transaction.

Stakeholder Impact

• Shareholders: The grant of SARs aims to align the CEO's financial incentives with long-term shareholder value creation, as the payout is tied to the appreciation of Pfizer's stock price.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• The Stock Appreciation Rights will vest over time, leading to settlement in Pfizer common stock on March 3, 2031, subject to the specified vesting requirements.

Key Dates

Keywords

Pfizer, PFE, Albert Bourla, Stock Appreciation Rights, SARs, Equity Compensation, Insider Transaction, Form 4, Executive Compensation